These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36566100)

  • 1. Outcomes of Grade Group 2 and 3 Prostate Cancer on Initial Versus Confirmatory Biopsy: Implications for Active Surveillance.
    Perera M; Jibara G; Tin AL; Haywood S; Sjoberg DD; Benfante NE; Carlsson SV; Eastham JA; Laudone V; Touijer KA; Fine S; Scardino PT; Vickers AJ; Ehdaie B
    Eur Urol Focus; 2023 Jul; 9(4):662-668. PubMed ID: 36566100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downgrading of grade group 2 intermediate-risk prostate cancer from biopsy to radical prostatectomy: Comparison of outcomes and predictors to identify potential candidates for active surveillance.
    Su ZT; Patel HD; Epstein JI; Pavlovich CP; Allaf ME
    Cancer; 2020 Apr; 126(8):1632-1639. PubMed ID: 32031685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer.
    Masic S; Cowan JE; Washington SL; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
    Eur Urol Oncol; 2018 Oct; 1(5):386-394. PubMed ID: 31158077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immediate versus delayed radical prostatectomy: updated outcomes following active surveillance of prostate cancer.
    Filippou P; Welty CJ; Cowan JE; Perez N; Shinohara K; Carroll PR
    Eur Urol; 2015 Sep; 68(3):458-63. PubMed ID: 26138041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance.
    Kaye DR; Qi J; Morgan TM; Linsell S; Ginsburg KB; Lane BR; Montie JE; Cher ML; Miller DC;
    BJU Int; 2019 May; 123(5):846-853. PubMed ID: 30248225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of Delayed Radical Prostatectomy on Recurrence Outcomes After Initial Active Surveillance: Results from a Large Institutional Cohort.
    Shee K; Cowan JE; Washington SL; Shinohara K; Nguyen HG; Cooperberg MR; Carroll PR
    Eur Urol Oncol; 2024 Aug; 7(4):838-843. PubMed ID: 38057193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort.
    Waisman Malaret AJ; Chang P; Zhu K; Zheng Y; Newcomb LF; Liu M; McKenney JK; Brooks JD; Carroll P; Dash A; Filson CP; Gleave ME; Liss M; Martin FM; Morgan TM; Nelson PS; Lin DW; Wagner AA
    J Urol; 2022 Apr; 207(4):805-813. PubMed ID: 34854745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance.
    Balakrishnan AS; Cowan JE; Cooperberg MR; Shinohara K; Nguyen HG; Carroll PR
    J Urol; 2019 Sep; 202(3):506-510. PubMed ID: 30958738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer.
    Jayadevan R; Felker ER; Kwan L; Barsa DE; Zhang H; Sisk AE; Delfin M; Marks LS
    JAMA Netw Open; 2019 Sep; 2(9):e1911019. PubMed ID: 31509206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study.
    Erickson AM; Luzzago S; Semjonow A; Vasarainen H; Laajala TD; Musi G; de Cobelli O; Mirtti T; Rannikko A
    Eur Urol Oncol; 2018 Sep; 1(4):268-275. PubMed ID: 31100247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Definitive pathology at radical prostatectomy is commonly favorable in men following initial active surveillance.
    Hong SK; Sternberg IA; Keren Paz GE; Kim PH; Touijer KA; Scardino PT; Eastham JA
    Eur Urol; 2014 Aug; 66(2):214-9. PubMed ID: 23954083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-Stage Prostate Cancer.
    Chappidi MR; Bell A; Cowan JE; Greenberg SA; Lonergan PE; Washington SL; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
    J Urol; 2022 May; 207(5):1001-1009. PubMed ID: 34981949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined MRI-targeted Plus Systematic Confirmatory Biopsy Improves Risk Stratification for Patients Enrolling on Active Surveillance for Prostate Cancer.
    O'Connor LP; Wang AZ; Yerram NK; Lebastchi AH; Ahdoot M; Gurram S; Zeng J; Mehralivand S; Harmon S; Merino MJ; Parnes HL; Choyke PL; Turkbey B; Wood BJ; Pinto PA
    Urology; 2020 Oct; 144():164-170. PubMed ID: 32679272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percentage Gleason pattern 4 and PI-RADS score predict upgrading in biopsy Grade Group 2 prostate cancer patients without cribriform pattern.
    van der Slot MA; Seyrek N; Kweldam CF; den Bakker MA; Busstra MB; Gan M; Klaver S; Rietbergen JBW; van Leenders GJLH
    World J Urol; 2022 Nov; 40(11):2723-2729. PubMed ID: 36190529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS Study.
    Luiting HB; Remmers S; Boevé ER; Valdagni R; Chiu PK; Semjonow A; Berge V; Tully KH; Rannikko AS; Staerman F; Roobol MJ
    Eur Urol Oncol; 2022 Dec; 5(6):651-658. PubMed ID: 35437217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    Eur Urol; 2017 Jun; 71(6):907-912. PubMed ID: 27876305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance.
    Kornberg Z; Cooperberg MR; Cowan JE; Chan JM; Shinohara K; Simko JP; Tenggara I; Carroll PR
    J Urol; 2019 Oct; 202(4):702-709. PubMed ID: 31026214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed radical prostatectomy after a period of active surveillance is not associated with the use of secondary treatments compared with immediate prostatectomy.
    Arcot R; Cher ML; Qi J; Linsell SM; Dunn RL; George AK; Montie JE; Ginsburg KB;
    Prostate; 2022 Feb; 82(3):323-329. PubMed ID: 34855239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
    Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
    J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer.
    Maggi M; Cowan JE; Fasulo V; Washington SL; Lonergan PE; Sciarra A; Nguyen HG; Carroll PR
    J Urol; 2020 Dec; 204(6):1222-1228. PubMed ID: 33157570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.